Search Results - Gillenwater, H.H

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC)

    Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC) by Scagliotti, G.V, Gillenwater, H.H, Brahmer, J.R, Govindan, R, Rosell, R, Belani, C.P, Atkins, J.N, Tye, L, Chao, R, Socinski, M.A

    Published in Clinical lung cancer
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

    TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA by Siddiqi, T., Dorritie, K.A., Soumerai, J.D., Stephens, D.M., Dubovsky, J.A., Gillenwater, H.H., Gong, L., Thorpe, J., Yang, L., Wierda, W.G.

    Published in Hematological oncology
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC)

    6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC) by Govindan, R, Brahmer, J.R, Novello, S, Rosell, R, Belani, C.P, Atkins, J.N, Gillenwater, H.H, Tye, L, Chao, R.C, Socinski, M.A

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Phase I trial of topotecan (T) carboplatin (C) and etoposide (E) for extensive stage small cell lung cancer (ES-SCLC)

    Phase I trial of topotecan (T) carboplatin (C) and etoposide (E) for extensive stage small cell lung cancer (ES-SCLC) by Gillenwater, H.H, McCune, J.S, Donahue, A.E, Faucette, S.R, Shifflett, S, Lindley, C, Socinski, M.A

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Second-line (SL) weekly paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P)

    Second-line (SL) weekly paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P) by Socinski, M.A, Kies, M, Unger, P, Peterman, A, Gillenwater, H.H, Schell, M, Bakri, K

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: